{"id":77585,"date":"2026-02-19T00:03:40","date_gmt":"2026-02-19T00:03:40","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/"},"modified":"2026-02-19T00:03:40","modified_gmt":"2026-02-19T00:03:40","slug":"a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/","title":{"rendered":"A World-First in Neonatal Care: Japan Approves Prolacta Bioscience&#8217;s 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants"},"content":{"rendered":"<div>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1361490\/Prolacta_Bioscience_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p class=\"prntac\"><b>Japan&#8217;s<\/b>\u00a0<b>Ministry of Health, Labour and Welfare<\/b>\u00a0<b>(MHLW)<\/b>\u00a0<b>Approves <\/b><b>PreemieFort\u00ae\u00a0Enteral Solution\u00a0as <\/b><b>Prescription <\/b><b>Medicine\u00a0in the NICU<\/b>\u00a0<\/p>\n<p><span class=\"legendSpanClass\">DUARTE, Calif.<\/span>, <span class=\"legendSpanClass\">Feb. 19, 2026<\/span> \/PRNewswire\/ &#8212;\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4622166-1&amp;h=2672852274&amp;u=https%3A%2F%2Fwww.prolacta.com%2Fau%2F&amp;a=Prolacta+Bioscience%C2%AE%C2%A0\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">Prolacta Bioscience\u00ae\u00a0<\/a>today announced that\u00a0Japan&#8217;s\u00a0Ministry of Health,\u00a0Labour\u00a0and Welfare\u00a0(MHLW)\u00a0has approved\u00a0PreemieFort\u00ae\u00a0Enteral Solution, a\u00a0100% human milk-based fortifier,\u00a0as a prescription drug for\u00a0very\u00a0low birth weight infants, infants with congenital gastrointestinal disorders or congenital heart diseases, and those recovering from gastrointestinal surgery.\u00a0This regulatory milestone was achieved in partnership with the\u00a0Clinigen\u00a0Group, which serves as Marketing Authorization Holder and distributor in Japan.\u00a0PreemieFort\u00a0is currently marketed under the brand name &#8220;Humavant&#8221; outside of the U.S., Canada, and Japan.\u00a0\u00a0<\/p>\n<p>The landmark regulatory decision\u00a0validates\u00a0the critical role of Prolacta&#8217;s 100% human milk-based fortifiers for the most fragile infants and sets a powerful precedent for neonatal intensive care units (NICUs) worldwide.\u00a0\u00a0<\/p>\n<p>&#8220;Japan&#8217;s approval of\u202fPreemieFort\u202fas a prescription drug reflects the strength of the clinical\u202fevidence and the pharmaceutical grade processing that stands up to the rigor of Japan&#8217;s\u202fstringent\u202fregulatory and quality requirements,&#8221; said\u202fScott\u202fElster, CEO of Prolacta Bioscience.\u202f&#8221;The pivotal\u202fJapanese clinical study\u202fadds to the extensive evidence supporting the benefits of Prolacta&#8217;s exclusive human milk-based diet for critically ill and fragile\u202fpremature infants.&#8221;\u202f\u00a0\u202f<\/p>\n<p>Clinical evidence generated in Japan from\u00a0the\u00a0JASMINE\u00a0trial (&#8220;A Randomized, Controlled Study to Assess Growth and Safety of the Exclusive Human Milk Diet (EHMD) in Very Low Birth Weight (VLBW) Infants&#8221;) informed Japan&#8217;s world-class Pharmaceuticals and Medical Devices Agency&#8217;s (PMDA) review.\u00a0\u00a0The Japanese-led\u00a0phase III, randomized, controlled, open-label, multicenter trial evaluated\u00a0growth and safety associated with Prolacta&#8217;s 100% human milk-based fortifiers,\u00a0demonstrating\u00a0significantly better growth in VLBW infants with no change in morbidity or mortality.\u00a0<\/p>\n<p>Japan is recognized as a global leader in neonatal care, with among the highest preterm survival rates and lowest rates of necrotizing enterocolitis (NEC),<sup>1,2<\/sup>\u00a0a life-threatening intestinal disease primarily affecting premature infants. By granting pharmaceutical approval to\u00a0PreemieFort, Japan is affirming that Prolacta&#8217;s human milk-based fortifiers, free from cow milk,\u00a0are not simply a nutritional choice but an\u00a0Rx\u00a0medicine\u00a0in the NICU.\u00a0\u00a0\u00a0<\/p>\n<p>Japan&#8217;s\u00a0approval includes three Prolacta products \u2014\u00a0<b>PreemieFort\u00a0Enteral Solution\u00a06,\u00a0PreemieFort\u00a0Enteral Solution\u00a08\u00a0<\/b>(Humavant+6 and Humavant+8\u00a0human milk-based fortifiers\u00a0outside the U.S., Canada, and Japan), and\u00a0<b>PreemieFort\u00a0Enteral Solution\u00a0CF\u00a0<\/b>(Humavant CR human milk caloric fortifier outside the U.S., Canada, and Japan) \u2014 which provide concentrated nutrition to support growth by delivering essential calories and nutrients, while retaining the highest level of human milk bioactivity.\u00a0\u00a0<\/p>\n<p>The\u00a0approval\u00a0demonstrates\u00a0clinical confidence in the benefits and safety of\u00a0PreemieFort\u00a0human milk-based fortifiers across a wider range of vulnerable infants with complex nutritional needs.\u00a0\u00a0<\/p>\n<p>&#8220;In the NICU, what we feed our smallest patients can influence their entire life,&#8221; said\u00a0Kate Tauber,\u00a0MD,\u00a0MA, professor of pediatrics and director\u00a0of the\u00a0Human Milk Program\u00a0at\u00a0Bernard and Millie Duker Children&#8217;s Hospital.\u00a0&#8220;Human milk-based fortifiers should be held to the same expectations as other therapies, consistent, tightly controlled, and safe. Prolacta&#8217;s commitment to pharmaceutical-quality manufacturing requirements helps protect vulnerable infants and supports\u00a0better outcomes.&#8221;\u00a0<\/p>\n<p>Prolacta maintains the industry&#8217;s strictest quality and safety standards for screening, testing, and\u00a0processing\u00a0donor milk \u2014 standards that extend through pharmaceutical grade product manufacturing.\u00a0Together, these\u00a0controls earned Japan&#8217;s prescription\u00a0drug\u00a0approval,\u00a0one of the world&#8217;s highest regulatory benchmarks.<\/p>\n<p><b>About Prolacta Bioscience<\/b> <br \/>Prolacta Bioscience\u00ae is the global leader in human milk-based nutrition, dedicated to improving health outcomes for critically ill and premature infants. The company&#8217;s 100% human milk-based fortifiers and formulas have been used in more than 125,000 vulnerable premature infants worldwide.<sup>3<\/sup>\u00a0In a global first, Japan granted Prolacta&#8217;s\u00a0PreemieFort\u00ae fortifiers prescription drug status in late 2025 for very\u00a0low birth weight infants, infants with congenital gastrointestinal disorders or congenital heart diseases, and those recovering from gastrointestinal surgery. Prolacta operates pharmaceutical-grade\u00a0human milk\u00a0processing facilities\u00a0and\u00a0maintains\u00a0the industry&#8217;s strictest quality and safety standards,\u00a0with\u00a0more than 20\u00a0tests to screen donor milk\u00a0and the use of vat pasteurization to\u00a0inactivate pathogens and\u00a0ensure safety.\u00a0Its\u00a0vat pasteurization\u00a0also\u00a0preserves\u00a0the bioactive components of human milk that support immune protection, gut development, and\u00a0growth\u00a0\u2014\u00a0benefits\u00a0that are\u00a0especially\u00a0important for\u00a0premature\u00a0and medically fragile infants.<sup>4-6<\/sup>\u00a0\u00a0Vat pasteurization keeps human milk closer to its natural state than other processing methods, while still ensuring safety.\u00a0Prolacta has built a secure, independent donor milk supply chain supported by long-term partnerships with thousands of rigorously screened donors, ensuring ample supply to meet NICU demand.\u00a0Prolacta&#8217;s products have been evaluated in over 30 peer-reviewed clinical studies,\u00a0demonstrating\u00a0the short- and long-term health benefits of its patented human milk-based fortifiers and formulas.\u00a0Learn more\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4622166-1&amp;h=2327171087&amp;u=https%3A%2F%2Fwww.prolacta.com%2Fau%2F&amp;a=online%C2%A0\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">online\u00a0<\/a>or at\u00a0<u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4622166-1&amp;h=139812056&amp;u=https%3A%2F%2Fx.com%2Fprolacta&amp;a=X\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">X<\/a><\/u>,\u00a0<u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4622166-1&amp;h=2476846122&amp;u=https%3A%2F%2Fwww.instagram.com%2Fprolacta_bioscience%2F&amp;a=Instagram\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">Instagram<\/a><\/u>,\u00a0<u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4622166-1&amp;h=2823934876&amp;u=http%3A%2F%2Fwww.facebook.com%2Fprolacta&amp;a=Facebook\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">Facebook<\/a><\/u>,\u00a0<u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4622166-1&amp;h=283487671&amp;u=https%3A%2F%2Fwww.tiktok.com%2Ftag%2Fprolactabioscience&amp;a=TikTok\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">TikTok<\/a><\/u>,\u00a0and\u00a0<u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4622166-1&amp;h=2781636252&amp;u=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fprolacta-bioscience%2F&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">LinkedIn<\/a><\/u>.\u00a0<\/p>\n<p><b>Media Contact:<\/b> <br \/>Loren\u00a0Kosmont <br \/><a href=\"mailto:Lkosmont@prolacta.com\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">Lkosmont@prolacta.com<\/a> <br \/>310-721-9444\u00a0<\/p>\n<p><b>References\u00a0<\/b>\u00a0<\/p>\n<ol type=\"1\">\n<li>Kusuda S, Bennett MV, Gould JB, et al. Comparative analysis of necrotizing enterocolitis in preterm infants born in Japan and born to mothers of Japanese ethnicity in California. Sci Rep. 2025;15:9943. doi:10.1038\/s41598-025-92393-y<\/li>\n<li>Isayama T. The clinical management and outcomes of extremely preterm infants in Japan: past, present, and future.\u00a0Transl\u00a0Pediatr. 2019;8(3):199-211. doi:10.21037\/tp.2019.07.10\u00a0<\/li>\n<li>Data on file; estimated number of premature infants fed\u00a0Prolacta&#8217;s products from January 2007 to May 2025.\u00a0<\/li>\n<li>Ozturk G,\u00a0Paviani\u00a0B, Rai R, et al. Investigating milk fat globule structure, size, and functionality after thermal processing and homogenization of human milk. Foods. 2024;13(8):1242. doi:10.3390\/foods13081242\u00a0<\/li>\n<li>Liang N, Koh J, Kim BJ, et al. Structural and functional changes of bioactive proteins in donor human milk treated by vat-pasteurization, retort sterilization, ultra-high-temperature sterilization, freeze-thawing\u00a0and homogenization. Front\u00a0Nutr. Published online September 15, 2022. doi:10.3389\/fnut.2022.926814\u00a0<\/li>\n<li>Meredith-Dennis L,\u00a0Xu G,\u00a0Goonatilleke\u00a0E,\u00a0Lebrilla\u00a0CB, Underwood MA, Smilowitz JT. Composition and variation of macronutrients, immune proteins, and human milk oligosaccharides in human milk from nonprofit and commercial milk banks. J Hum\u00a0Lact. 2018;34(1):120-129. doi:10.1177\/0890334417710635\u00a0<\/li>\n<\/ol>\n<p>Logo &#8211; <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4622166-1&amp;h=2002145912&amp;u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1361490%2FProlacta_Bioscience_Logo.jpg&amp;a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1361490%2FProlacta_Bioscience_Logo.jpg\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">https:\/\/mma.prnasia.com\/media2\/1361490\/Prolacta_Bioscience_Logo.jpg?p=medium600<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Japan&#8217;s\u00a0Ministry of Health, Labour and Welfare\u00a0(MHLW)\u00a0Approves PreemieFort\u00ae\u00a0Enteral Solution\u00a0as Prescription Medicine\u00a0in the NICU\u00a0 DUARTE, Calif., Feb. 19, 2026 \/PRNewswire\/ &#8212;\u00a0Prolacta Bioscience\u00ae\u00a0today announced that\u00a0Japan&#8217;s\u00a0Ministry of Health,\u00a0Labour\u00a0and Welfare\u00a0(MHLW)\u00a0has approved\u00a0PreemieFort\u00ae\u00a0Enteral Solution, a\u00a0100% human milk-based fortifier,\u00a0as a prescription drug for\u00a0very\u00a0low birth weight infants, infants with congenital gastrointestinal disorders or congenital heart diseases, and those recovering from gastrointestinal surgery.\u00a0This regulatory milestone [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-77585","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>A World-First in Neonatal Care: Japan Approves Prolacta Bioscience&#039;s 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A World-First in Neonatal Care: Japan Approves Prolacta Bioscience&#039;s 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants\" \/>\n<meta property=\"og:description\" content=\"Japan&#8217;s\u00a0Ministry of Health, Labour and Welfare\u00a0(MHLW)\u00a0Approves PreemieFort\u00ae\u00a0Enteral Solution\u00a0as Prescription Medicine\u00a0in the NICU\u00a0 DUART\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-19T00:03:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/1361490\/Prolacta_Bioscience_Logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"A World-First in Neonatal Care: Japan Approves Prolacta Bioscience&#8217;s 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants\",\"datePublished\":\"2026-02-19T00:03:40+00:00\",\"dateModified\":\"2026-02-19T00:03:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/\"},\"wordCount\":1000,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/\",\"name\":\"A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-02-19T00:03:40+00:00\",\"dateModified\":\"2026-02-19T00:03:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A World-First in Neonatal Care: Japan Approves Prolacta Bioscience&#8217;s 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/","og_locale":"en_US","og_type":"article","og_title":"A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants","og_description":"Japan&#8217;s\u00a0Ministry of Health, Labour and Welfare\u00a0(MHLW)\u00a0Approves PreemieFort\u00ae\u00a0Enteral Solution\u00a0as Prescription Medicine\u00a0in the NICU\u00a0 DUART","og_url":"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-02-19T00:03:40+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/1361490\/Prolacta_Bioscience_Logo.jpg?p=medium600"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"A World-First in Neonatal Care: Japan Approves Prolacta Bioscience&#8217;s 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants","datePublished":"2026-02-19T00:03:40+00:00","dateModified":"2026-02-19T00:03:40+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/"},"wordCount":1000,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/","url":"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/","name":"A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-02-19T00:03:40+00:00","dateModified":"2026-02-19T00:03:40+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/a-world-first-in-neonatal-care-japan-approves-prolacta-biosciences-100-human-milk-based-fortifiers-as-a-prescription-drug-for-vulnerable-infants\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"A World-First in Neonatal Care: Japan Approves Prolacta Bioscience&#8217;s 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/77585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=77585"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/77585\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=77585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=77585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=77585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}